JonesResearch analyst Justin Walsh initiated coverage of Serina Therapeutics (SER) with a Buy rating and $11 price target. Serina is a drug ...

Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch. “Continuous ...

SPN-820 was well-tolerated with few adverse events. Earlier this month, the FDA approved Supernus Pharmaceuticals’ ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830 ...

SPN-820 was well-tolerated with few adverse events. Earlier this month, the FDA approved Supernus Pharmaceuticals’ ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first ...

ONAPGO (apomorphine hydrochloride), formerly known as SPN-830, approved by the U.S. Food and Drug Administration and will be launched in the second quarter of 2025. Full year 2025 guidance for ...

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced ...

Supernus also announced FDA approval for ONAPGO, its treatment for motor fluctuations in adults with advanced Parkinson's disease. The company plans to launch ONAPGO in the second quarter of 2025.

The company expects operating earnings (loss) between $(15) million and $10 million. Supernus also announced FDA approval for ONAPGO, its treatment for motor fluctuations in adults with advanced ...

Earlier this month, the FDA approved ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with ...

Earlier this month, the FDA approved ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with ...